Related Experiment Video
Updated: May 4, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms
Koen L A Vanderschuren1, Tom Sieverink1, Ronald Wilders1
1Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Meibergdreef 15, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.
Insights
Transforming growth factor beta 3 (TGF β 3) plays a key role in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) type 1. This review explores TGF β 3
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited condition leading to arrhythmias, heart failure, and sudden cardiac death.
- ARVD/C type 1 is linked to altered expression of transforming growth factor beta 3 (TGF β 3).
Purpose of the Study:
- To review proposed mechanisms underlying ARVD/C type 1.
- To elucidate the role of TGF β 3 in disease progression.
- To discuss the involvement of fibrogenesis, apoptosis, and the immune system.
Main Methods:
- Literature review of existing studies on ARVD/C mechanisms.
- Analysis of TGF β 3 signaling pathways (Smad, β -catenin).
- Discussion of apoptosis and immune system modulation in ARVD/C.
Main Results:
- TGF β 3 can promote fibrogenesis via Smad and/or β -catenin signaling.
- Apoptosis plays a role in ARVD/C pathogenesis.
- The immune system acts as a modulator and amplifier in ARVD/C onset and progression.
Conclusions:
- TGF β 3 is a significant factor in ARVD/C type 1.
- Understanding these molecular mechanisms is crucial for developing therapeutic strategies.
- Further research into immune system involvement may offer new treatment avenues.
Abstract:
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy associated with cardiac arrhythmias originating in the right ventricle, heart failure, and sudden cardiac death. Development of ARVD/C type 1 has been attributed to differential expression of transforming growth factor beta 3 (TGF β 3). Several mechanisms underlying the molecular basis of ARVD/C type 1 have been proposed. Evaluating previously described mechanisms might elucidate how TGF β 3 contributes to disease progression in ARVD/C type 1. Here we review how TGF β 3 can induce fibrogenesis through Smad and/or β -catenin signaling. Moreover, the role of apoptosis is addressed. Finally the extent to which the immune system has been demonstrated to be a modulating and amplifying agent in the onset and progression of ARVD/C in general is discussed.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mechanism of Cardiac Arrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

